ESTIMATION OF DIACEREIN TOLERABILITY IN REAL CLINICAL PRACTICE: RESULTS OF THE RACADA (RETROSPECTIVE ASSESSMENT OF CLINICAL ASPECTS OF USING DIAFLEX IN OSTEOARTHRITIS)

 

Diacerein (DR) is widely used to treat osteoarthritis  (OA) and belongs to a group of symptomatic slow-acting drugs for OA (SYSADOA). One of the major benefits of this drug is a low risk of serious adverse events(AE). However,Russiahas not conducted  its own large-scale trials of the safety of DR despite its popularity.

Objective: to estimate the frequency of AE of DR (Diaflex®, Romfarm) in real clinical practice.

Subjects and methods. The use of DR was retrospectively analyzed in 3479 patients (60.4% women and 39.6% men; mean age 57.6±12.6 years) with OA and back pain. DR was used in a dose of 100 mg/day; treatment results were assessed following 30 days. The patients received combination  therapy: in addition to DR, 62.6% took nonsteroidal anti-inflammatory drugs, as well as myorelaxants, local glucocorticoid injections, other SYSADOA, etc. The efficiency of therapy (visual analogue scale (VAS) pain changes and treatment satisfaction), and the frequency and nature of AE were assessed.

 Results. Combination therapy using DR was effective in the majority of patients: VAS pain intensity decreased from 71.2±17.5 to 22.6±16.3 mm; 76% of the patients rated their treatment results as good or excellent. Major AE involved the gastrointestinal  tract; obvious gastralgia, nausea, and a sensation of heaviness were observed in only 1.7, 1.8, and 2.4% of the patients, respectively. There were frequent stools: 5.91±1.9 defecation episodes per week at baseline; 7.3±2.8 episodes per week after 30 days of DR administration (p < 0.001). Only 30 (0.86%) patients developed marked diarrhea. There was a considerable (more than two-fold higher than the upper reference limits) increase in alanine aminotransferase  and aspartate aminotransferase  (ALT/AST) levels in only 20 (0.57%) patients.

Conclusion. Combination treatment using DR is effective in reducing pain in patients with OA and low back pain. DR is well tolerated and rarely causes serious AE. Marked diarrhea and significantly elevated ALT/AST levels are seen in less than 1% of the patients taking

osteoarthrosis, back pain, diacerein, adverse events, diarrhea

1. Conaghan PG, Kloppenburg M, Schett G, Bijlsma JW; EULAR osteoarthritis ad hoc committee. Osteoarthritis research priorities: a report from a EULAR ad hoc expert committee. Ann Rheum Dis. 2014 Aug;73(8):1442–5. doi: 10.1136/annrheumdis-2013-204660. Epub 2014 Mar 13.

2. Smith E, Hoy DG, Cross M, et al. The global burden of other musculoskeletal disorders: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014 Aug;73(8):1462–9. doi: 10.1136/annrheumdis-2013-204680. Epub 2014 Mar 3.

3. Murphy L, Helmick CG. The impact of osteoarthritis in the United States: a population-health perspective. Am J Nurs. 2012 Mar;112(3 Suppl 1):S13–9. doi: 10.1097/01.NAJ.0000412646.80054.21.

4. Каратеев АЕ, Алексеева ЛИ, Филатова ЕГ и др. Обезболивающие препараты в терапевтической практике. Москва: ИМА-ПРЕСС; 2013. 134 с. [Karateev AE, Alexeyeva LI, Filatova EG, et al. Obezbolivayushchie preparaty v terapevticheskoi praktike [Analgesics agents in therapeutic practice]. Moscow: IMA-PRESS; 2013. 134 p.]

5. Балабанова РМ, Алексеева ЛИ. Ингибиция интерлейкина-1 — новый подход к лечению остеоартроза. Медицинский совет. 2010;7(7):40–2. [Balabanova RM, Alekseeva LI. Inhibition of interleukin-1 – a new approach to the treatment of osteoarthritis. Meditsinskii sovet. 2010;7(7):40–2. (In Russ.)].

6. Assessment report for diacerein containing medicinal products. 28 August 2014 EMA/527347/2014. На сайте: http://www.ema.europa.eu/

7. Zhang W, Doherty M, Arden N, et al. EULAR evidence based recommendations for the management of hip osteoarthritis: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis. 2005 May;64(5):669–81. Epub 2004 Oct 7. doi: 10.1136/ard.2004.028886

8. PRAC recommends suspension of diacerein-containing medicines. Committee cites concerns over gastro-intestinal side effects and liver toxicity. 6 December 2013 EMA/679264/2013/rev.2. На сайте: http://www.ema.europa.eu/9. Sharma A, Rathod R, Baliga VP. An open prospective study on postmarketing evaluation of the efficacy and tolerability of diacerein in osteo-arthritis of the knee (DOK). J Indian Med Assoc. 2008 Jan;106(1):54–6, 58.

9. Fidelix TS, Macedo CR, Maxwell LJ, Fernandes Moсa Trevisani V. Diacerein for osteoarthritis. Cochrane Database Syst Rev. 2014 Feb 10;2:CD005117. doi: 10.1002/14651858.CD005117.pub3.

10. Pelletier JP, Yaron M, Haraoui B, et al. Efficacy and safety of diacerein in osteoarthritis of the knee: a double-blind, placebocontrolled trial. The Diacerein Study Group. Arthritis Rheum. 2000 Oct;43(10):2339–48.

11. Pavelka K, Trc T, Karpas K, et al. The efficacy and safety of diacerein in the treatment of painful osteoarthritis of the knee: a randomized, multicenter, double-blind, placebo-controlled study with primary end points at two months after the end of a three-month treatment period. Arthritis Rheum. 2007 Dec;56(12):4055–64. doi 10.1002/art.23056

12. Moore RA, Moore OA, Derry S, et al. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010 Feb;69(2):374–9. doi: 10.1136/ard.2009.107805. Epub 2009 Apr 12.

13. Каратеев АЕ. Применение лактулозы для коррекции нарушений стула у больных ревматическими заболеваниями. Научно-практическая ревматология. 2008;(6):69–73. [Karateev AE. Lactulose administration for correction of defecation disorders in patients with rheumatic diseases. Nauchno-prakticheskaya revmatologiya = Rheumatology Science and Practice. 2008;(6):69–73. (In Russ.)]. doi: http://dx.doi.org/10.14412/1995-4484-2008-493

14. Dougados M, Nguyen M, Berdah L, et al. ECHODIAH Investigators Study Group. Evaluation of the structure-modifying effects of diacerein in hip osteoarthritis: ECHODIAH, a threeyear, placebo-controlled trial. Evaluation of the Chondromodulating Effect of Diacerein in OA of the Hip. Arthritis Rheum. 2001 Nov;44(11):2539–47.

15. Vial T, Mille R, Bory RM, Evreux JC. Acute hepatitis asociated with ingestion of of diacerein. Gastroenterol Clin Biol. 1997;21(10):795–6.

16. Renan X, Lepage M, Connan D, et al. Case report of fatal hepatitis from diacerein.